Patients who do not respond to the "usual" dose: Why terry fell off the dose-response curve

Journal of Psychiatric Practice

Volumn 15, Issue 6, 2009, Pages 460-466

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Montreal   (United States)

Author keywords

Adverse effects; Dose; Dose response curve; Efficacy; Outlier; Resistance; Response; Sensitivity

Indexed keywords

ANTIDEPRESSANT AGENT; PHENOTHIAZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL ASSESSMENT; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; HUMAN; NAUSEA; PATIENT; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC VARIATION; HUMANS; PATIENT DROPOUTS; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 75149139977     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000364288.01328.44     Document Type: Review

References (17)

1. Carruthers SG, Hoffman BB, Melmon KL, et al. Melmon and Morelli's clinical pharmacology, 4th edition. New York: McGraw-Hill; 2000.
2. Janicak PG, Davis JM, Preskorn SH, et al. Principles and practice of psychopharmacotherapy, 4th edition. Baltimore: Lippincott,Williams & Wilkins, 2006.
3. Preskorn SH, Flockhart D. 2010 guide to psychiatric drug interactions. Prim Psychiatry in press.
4. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part I). J Psychiatr Pract 2003;9:150-158
5. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part II). J Psychiatr Pract 2003;9:228-236
6. Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors, 1st edition. Caddo, OK.: Professional Communications, Inc., 1996.
7. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [11C]DASB positron emission tomography study. Am J Psychiatry 2004;161:826-835
8. Preskorn SH. Imipramine, mirtazapine, and nefazodone: Multiple targets. J Psychiatr Pract 2000;6:97-102.
9. Preskorn SH. Clinical application of the concept of relative potency: An example involving chlorpromazine and haloperidol. J Psychiatr Pract 2005;11:258-261
10. Preskorn, S. Clinical relevance of relative receptor binding affinity: Quetiapine and ziprasidone as examples. J Psychiatr Pract 2007;13:393-398
11. Hartigan-Go K, Bateman DN, Nyberg G, et al. Pharmacodynamics and drug action: Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 1996;60:543-553
12. Drolet B, Vincent F, Rail J, et al. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther 1999;288:1261-1268 (Pubitemid 29254167)
13. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-69
14. Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: Phenomenology, course, risk factors and role of therapeutic drug monitoring. J Clin Psychopharmacol 1990;10:88-95.
15. Giardina EG, Bigger JT Jr. Antiarrhythmic effect of imipramine hydrochloride in patients with ventricular premature complexes without psychological depression. Am J Cardiol 1982;50:172-179
16. Giardina EG, Louie M, Bigger JT Jr, et al. Antiarrhythmic plasma-concentration range of imipramine against ventricular premature depolarizations. Clin Pharmacol Ther 1983;34:284-289
17. Preskorn SH. How multiple medication use evolves and the importance of therapeutic trials: The slippery slide. J Psychiatr Pract 2008;14:170-175